Active Compound in Popular Heartburn Drug Pepcid Being Tested for COVID-19 Treatment
By HospiMedica International staff writers Posted on 29 Apr 2020 |
Illustration
A trial for famotidine, the active compound in the over-the-counter heartburn medication Pepcid, is underway at the Feinstein Institutes for Medical Research (Manhasset, NY, USA) to study if the drug can make a difference in the treatment of COVID-19 patients.
The researchers decided to conduct a drug trial for famotidine after encouraging reports from China. A review of 6,212 COVID-19 patient records revealed that a large number of survivors had been experiencing chronic heartburn and were taking famotidine instead of omeprazole (Prilosec) which is more expensive and preferred in the US and among the wealthier population in China. Hospitalized COVID-19 patients who were taking famotidine seemed to have a lower death rate of 14% as against 27% for patients who were not taking the drug.
Additionally, molecular modeling results also suggested that famotidine, which appears to bind to a key enzyme in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), could deliver results. Famotidine is believed to bind to an enzyme critical to COVID-19. Similar to how protease inhibitors, which are used to treat HIV, stop the virus, famotidine’s structure can stop the coronavirus from replicating, at least theoretically.
The Feinstein Institutes for Medical Research received clearance from the US Food and Drug Administration to conduct a trial using the intravenous version of famotidine. In addition to Gilead Sciences’ remdesivir and the anti-malarial drug hydroxychloroquine, the researchers are now also assessing famotidine in a small clinical trial which has enrolled 187 critical COVID-19 patients so far, including several on ventilators, and aims for a total of 1174 people. In the trial the patients are being intravenously administered nine times the amount of famotidine that a person would normally take to treat heartburn,
The researchers have been keeping the clinical trial of famotidine under wraps to ensure sufficient supply for their study, as well as avoid a rush to medication stores for the drug which would deny people with heartburn or stomach ulcers access to the drug.
Related Links:
Feinstein Institutes for Medical Research
The researchers decided to conduct a drug trial for famotidine after encouraging reports from China. A review of 6,212 COVID-19 patient records revealed that a large number of survivors had been experiencing chronic heartburn and were taking famotidine instead of omeprazole (Prilosec) which is more expensive and preferred in the US and among the wealthier population in China. Hospitalized COVID-19 patients who were taking famotidine seemed to have a lower death rate of 14% as against 27% for patients who were not taking the drug.
Additionally, molecular modeling results also suggested that famotidine, which appears to bind to a key enzyme in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), could deliver results. Famotidine is believed to bind to an enzyme critical to COVID-19. Similar to how protease inhibitors, which are used to treat HIV, stop the virus, famotidine’s structure can stop the coronavirus from replicating, at least theoretically.
The Feinstein Institutes for Medical Research received clearance from the US Food and Drug Administration to conduct a trial using the intravenous version of famotidine. In addition to Gilead Sciences’ remdesivir and the anti-malarial drug hydroxychloroquine, the researchers are now also assessing famotidine in a small clinical trial which has enrolled 187 critical COVID-19 patients so far, including several on ventilators, and aims for a total of 1174 people. In the trial the patients are being intravenously administered nine times the amount of famotidine that a person would normally take to treat heartburn,
The researchers have been keeping the clinical trial of famotidine under wraps to ensure sufficient supply for their study, as well as avoid a rush to medication stores for the drug which would deny people with heartburn or stomach ulcers access to the drug.
Related Links:
Feinstein Institutes for Medical Research
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans